Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study

• click to rate

  Posted by Two Blokes Jul 3 - Filed in Stock - 4 views
  
  NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.